Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence.

Trial Profile

Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Dec 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Overactive bladder; Urinary incontinence
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBARK
  • Sponsors Allergan
  • Most Recent Events

    • 12 Dec 2016 Results published in the Journal of Urology
    • 09 Oct 2015 Results of post-hoc analysis presented at the 45th Annual Meeting of the International Continence Society
    • 15 Apr 2014 Pooled analysis assessing efficacy outcomes according to the presence of urinary tract infection or use of clean intermittent catheters presented at the 29th Congress of the European Association of Urology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top